Patents by Inventor Riitta Lahesmaa

Riitta Lahesmaa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • L1TD1 AS PREDICTIVE BIOMARKER OF COLON CANCER
    Publication number: 20210285053
    Abstract: The present invention relates to biomarkers, such as L1NE-1 type transposase domain containing 1 (L1TD1) as predictive prognostic markers of colon cancer. The invention also relates to a method of prognosing colon cancer, and to a kit for use in said method.
    Type: Application
    Filed: May 29, 2019
    Publication date: September 16, 2021
    Applicant: Turun yliopisto
    Inventors: Deepankar CHAKROBORTY, Emani Maheswara REDDY, Laura ELO, Riitta LAHESMAA, Ari RISTIMÄKI, Caj HAGLUND
  • MEANS AND METHODS FOR DETERMINING RISK OF TYPE-1 DIABETES BY SERUM PROTEIN BIOMARKERS
    Publication number: 20210080458
    Abstract: The present invention relates to methods for predicting a risk of a subject for Type 1 diabetes (T1D) on the basis of expression levels of protein markers in a sample obtained from the subject. The present invention also relates to in vitro kits for use in said methods.
    Type: Application
    Filed: November 23, 2020
    Publication date: March 18, 2021
    Applicant: TURUN YLIOPISTO
    Inventors: Robert Moulder, Santosh BHOSALE, David GOODLETT, Harri LÄHDESMÄKI, Olli SIMELL, Riitta LAHESMAA
  • Means and methods for determining risk of type-1 diabetes by serum protein biomarkers
    Patent number: 10877034
    Abstract: The present invention relates to methods for predicting a risk of a subject for Type 1 diabetes (T1D) on the basis of expression levels of protein markers in a sample obtained from the subject. The present invention also relates to in vitro kits for use in said methods.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: December 29, 2020
    Assignee: TURUN YLIOPISTO
    Inventors: Robert Moulder, Santosh Bhosale, David Goodlett, Harri Lähdesmäki, Olli Simell, Riitta Lahesmaa
  • INTERLEUKIN 32 AS A BIOMARKER OF TYPE 1 DIABETES
    Publication number: 20200264192
    Abstract: The present invention relates to interleukin 32 (IL-32) as a predictive marker of Type 1 diabetes (T1D). The invention also relates to a method of predicting an individual's risk of or progression towards T1D, and to a kit for use in said method.
    Type: Application
    Filed: September 27, 2018
    Publication date: August 20, 2020
    Applicant: TURUN YLIOPISTO
    Inventors: Juhi SOMANI, Soile TUOMELA, Henna KALLIONPÄÄ, Riitta LAHESMAA, Harri LÄHDESMÄKI, Riikka LUND, Mikael KNIP
  • Method of Predicting Risk for Type 1 Diabetes
    Publication number: 20190136322
    Abstract: The present invention relates to methods, transcriptome profiles and kits useful for determining, before seroconversion, the risk that an individual will develop Type 1 diabetes (T1D).
    Type: Application
    Filed: December 21, 2018
    Publication date: May 9, 2019
    Inventors: Henna Kallionpaa, Laura L. Elo, Essi Laajala, Juha Mykkanen, Olli Simell, Riitta Lahesmaa, Harri Lahdesmaki, Lingjia Kong, Soile Tuomela, Niina Lietzen
  • MEANS AND METHODS FOR DETERMINING RISK OF TYPE-1 DIABETES BY SERUM PROTEIN BIOMARKERS
    Publication number: 20170160276
    Abstract: The present invention relates to methods for predicting a risk of a subject for Type 1 diabetes (T1D) on the basis of expression levels of protein markers in a sample obtained from the subject. The present invention also relates to in vitro kits for use in said methods.
    Type: Application
    Filed: June 18, 2015
    Publication date: June 8, 2017
    Applicant: TURUN YLIOPISTO
    Inventors: Robert MOULDER, Santosh BHOSALE, David GOODLETT, Harri LÄHDESMÄKI, Olli SIMELL, Riitta LAHESMAA
  • Method of Predicting Risk for Type 1 Diabetes
    Publication number: 20160145687
    Abstract: The present invention relates to methods, transcriptome profiles and kits useful for determining, before seroconversion, the risk that an individual will develop Type 1 diabetes (T1D).
    Type: Application
    Filed: June 25, 2014
    Publication date: May 26, 2016
    Inventors: Henna Kallionpaa, Laura L. Elo, Essi Laajala, Juha Mykkanen, Olli Simell, Riitta Lahesmaa, Harri Lahdesmaki, Lingjia Kong, Soile Tuomela, Niina Lietzen
  • Methods and means related to diseases
    Patent number: 8143029
    Abstract: The present invention relates to the fields of genetics and oncology and provides methods for detecting cutaneous T-cell lymphomas (CTCL) or susceptibility to CTCL. Specifically, the present invention relates to a novel method for the diagnosis and follow-up of CTCL or CTCL subtype, the method comprising determination of expression of one or more genes, gene fragments or gene products. The present invention further relates to a novel method of detecting the response to CTCL therapy, the method comprising determining expression of one or more genes or gene fragments or gene products in a biological sample. The present invention further relates to a novel method of developing or improving CTCL therapy or developing anti-CTCL medicament, the method comprising screening agents affecting one or several of the genes or gene products. The present invention further relates to a novel method of treating CTCL patients, the method comprising affecting one or several of the genes or gene products.
    Type: Grant
    Filed: December 21, 2006
    Date of Patent: March 27, 2012
    Assignee: Valipharma
    Inventors: Annamari Ranki, Sonja Hahtola, Leena Karenko, Soile Tuomela, Riitta Lahesmaa, Kai J. E Krohn
  • Method of identifying a compound capable of modulating the Th2 polarization of CD4+ lymphocytes
    Patent number: 7989172
    Abstract: The present invention provides methods utilizing novel target genes related to immune-mediated diseases, such as asthma, allergy and autoimmune diseases. The invention is based on a molecular level description of the polarization of CD4+ precursor cells (Thp) from which T helper cells are known to originate. Particularly, the present invention provides a method of identifying a compound capable of modulating the polarization of CD4+ lymphocytes. The invention is also related to a method for assessing the presence of, or disposition to, an immune-related disorder in a subject.
    Type: Grant
    Filed: September 16, 2005
    Date of Patent: August 2, 2011
    Assignee: Turun Yliopisto
    Inventors: Riikka Lund, Riitta Lahesmaa
  • Methods and Means Related to Diseases
    Publication number: 20100035971
    Abstract: The present invention relates to the fields of genetics and oncology and provides methods for detecting cutaneous T-cell lymphomas (CTCL) or susceptibility to CTCL. Specifically, the present invention relates to a novel method for the diagnosis and follow-up of CTCL or CTCL subtype, the method comprising determination of expression of one or more genes, gene fragments or gene products. The present invention further relates to a novel method of detecting the response to CTCL therapy, the method comprising determining expression of one or more genes or gene fragments or gene products in a biological sample. The present invention further relates to a novel method of developing or improving CTCL therapy or developing anti-CTCL medicament, the method comprising screening agents affecting one or several of the genes or gene products. The present invention further relates to a novel method of treating CTCL patients, the method comprising affecting one or several of the genes or gene products.
    Type: Application
    Filed: December 21, 2006
    Publication date: February 11, 2010
    Inventors: Annamari Ranki, Sonja Hahtola, Leena Karenko, Soile Tuomela, Riitta Lahesmaa, Kai J.E. Krohn
  • Methods utilizing target genes related to immune-mediated diseases
    Patent number: 7659077
    Abstract: The present invention provides methods utilizing novel target genes related to immune-mediated diseases, such as asthma, allergy and autoimmune diseases. The invention is based on a molecular level description of the polarization of CD4+ precursor cells (Thp) from which T helper cells are known to originate. Particularly, the present invention provides a method of identifying a compound capable of modulating the polarization of CD4+ lymphocytes. The invention is also related to a method for assessing the presence of, or a predisposition to, an immune-related disorder in a subject.
    Type: Grant
    Filed: March 17, 2004
    Date of Patent: February 9, 2010
    Inventors: Riikka Lund, Zhi Chen, Riitta Lahesmaa
  • Methods for the Utilizaton of Novel Target Genes Related to Immune-Mediated Diseases
    Publication number: 20080168570
    Abstract: The present invention provides methods utilizing novel target genes related to immune-mediated diseases, such as asthma, allergy and autoimmune diseases. The invention is based on a molecular level description of the polarization of CD4+ precursor cells (Thp) from which T helper cells are known to originate. Particularly, the present invention provides a method of identifying a compound capable of modulating the polarization of CD4+ lymphocytes. The invention is also related to a method for assessing the presence of, or disposition to, an immune-related disorder in a subject.
    Type: Application
    Filed: September 16, 2005
    Publication date: July 10, 2008
    Inventors: Riikka Lund, Riitta Lahesmaa